Irritable Bowel Syndrome

Detailed Overview

IBS is one of the most common functional GI disorders, significantly impacting patients' quality of life. The pathophysiology is complex, involving visceral hypersensitivity, altered gastrointestinal motility, intestinal inflammation, and alterations in the gut microbiome. Diagnosis relies on symptom-based criteria, specifically the Rome IV criteria, after excluding warning signs. Management requires a biopsychosocial approach, including dietary modifications, targeted pharmacotherapy based on the predominant bowel habit, and behavioral therapies.

Epidemiology & Demographics

Global prevalence is estimated at 5% to 10%. It is 1.5 to 2 times more common in women than in men. Peak age of onset is typically between 20 and 30 years old, with prevalence decreasing in those over 50 years of age.

Etiological Mechanism

The exact etiology is unknown but is multifactorial. It involves dysregulation of the gut-brain axis, genetic predisposition, and often follows a severe gastrointestinal infection (post-infectious IBS).

Primary Causes

While a single root cause is absent, primary triggers include prior acute gastroenteritis (Campylobacter, Salmonella), psychosocial stress, food intolerances (FODMAPs), and gut microbiome dysbiosis.

• Female Sex: Women are nearly twice as likely to develop IBS, possibly related to hormonal fluctuations.
• Prior GI Infection: A severe bout of bacterial or viral gastroenteritis increases the risk of developing post-infectious IBS by 6-fold.
• Psychological Stress: High levels of life stress, anxiety, or a history of abuse are strongly correlated with IBS onset and symptom exacerbation.

The core mechanisms involve visceral hypersensitivity, where normal bowel distension is perceived as painful due to altered central nervous system processing or sensitized enteric nerves. Altered GI motility leads to accelerated transit (IBS-D) or delayed transit (IBS-C). Increased intestinal permeability and low-grade mucosal inflammation, particularly increased mast cells in the terminal ileum and colon, contribute to symptom generation. Microbial dysbiosis alters fermentation of carbohydrates, producing excess gas and short-chain fatty acids.

Characteristic Clinical Presentation

• Abdominal Pain: Crampy, lower abdominal pain that is often related to defecation and exacerbated by emotional stress or eating.
• Altered Bowel Habits: Constipation (hard, lumpy stools), diarrhea (loose, watery stools), or alternating between both.
• Bloating: Sensation of abdominal fullness and visible distension, often worsening throughout the day.

Physical Examination Signs

• Mild lower abdominal tenderness on palpation

• Hemorrhoids: Due to chronic straining or frequent diarrhea.
• Nutritional Deficiencies: From extreme self-imposed dietary restrictions to avoid triggers.

Diagnostic Criteria & Guidelines

Rome IV Criteria: Recurrent abdominal pain, on average, at least 1 day/week in the last 3 months, associated with 2 or more of the following: 1) Related to defecation, 2) Associated with a change in frequency of stool, 3) Associated with a change in form (appearance) of stool. Symptoms must have started at least 6 months prior.

Differential Diagnosis

• Celiac Disease
• Inflammatory Bowel Disease (Crohn's, Ulcerative Colitis)
• Microscopic Colitis

Laboratory Tests & Biomarkers

• CBC: Normal (to rule out anemia indicating organic disease)
• C-Reactive Protein (CRP) / Fecal Calprotectin: Normal (rules out IBD; Fecal calprotectin < 50 mcg/g)
• Tissue Transglutaminase (tTG) IgA: Negative (rules out Celiac disease)

Imaging Modalities & Findings

• Colonoscopy: Macroscopically normal mucosa (indicated only if warning signs are present or age > 45)

• IBS-C
  Constipation-predominant: >25% of bowel movements are hard/lumpy stools and <25% are loose/watery stools.
• IBS-D
  Diarrhea-predominant: >25% of bowel movements are loose/watery and <25% are hard/lumpy.
• IBS-M
  Mixed: >25% of bowel movements are hard/lumpy and >25% are loose/watery.

Second-Line & Adjunctive Therapy

For IBS-C: Linaclotide 290 mcg PO daily. For IBS-D: Eluxadoline 100 mg PO BID or Rifaximin 550 mg PO TID for 14 days. For refractory pain: Amitriptyline 10-25 mg PO at bedtime.

Surgical & Procedural Management

None indicated.

Recommended Lifestyle Changes

• Low FODMAP diet for 2-6 weeks, followed by gradual reintroduction of specific fermentable carbohydrates.
• Moderate exercise (e.g., brisk walking, cycling) for 30 minutes 5 days a week.
• Cognitive Behavioral Therapy (CBT) or gut-directed hypnotherapy for stress management.

Patient Counseling & Advice

Reassure the patient that IBS is a chronic but benign condition that does not increase the risk of colon cancer. Emphasize the strong connection between stress, anxiety, and GI symptoms, and the importance of dietary compliance.

Follow-Up & Monitoring Schedule

Follow-up every 4-8 weeks when initiating new dietary therapies or pharmacotherapy to assess response using validated tools like the IBS-Symptom Severity Scale (IBS-SSS).

Preventive Strategies

Cannot be entirely prevented, but symptom flare-ups can be minimized through strict adherence to individualized dietary plans and stress-reduction techniques.

Chronic, relapsing-remitting course. Although it does not affect life expectancy, it can significantly impair quality of life if unmanaged. 50-70% of patients achieve satisfactory symptom control with combination therapy.